| Literature DB >> 26958320 |
Justin Parreno1, Elizabeth Delve2, Katarina Andrejevic1, Sabrina Paez-Parent3, Po-Han Wu3, Rita Kandel4.
Abstract
Nucleofection of chondrocytes has been shown to be an adequate method of transfection. Using Amaxa's nucleofection system, transfection efficiencies up to 89% were achievable for vector (pmaxGFP) and 98% for siRNA (siGLO) into passaged chondrocytes. However, such methods rely on costly commercial kits with proprietary reagents limiting its use in basic science labs and in clinical translation. Bovine-passaged chondrocytes were plated in serum reduced media conditionsand then nucleofected using various in laboratory-produced buffers. Cell attachment, confluency, viability, and transfection efficiency was assessed following nucleofection. For each parameter the buffers were scored and a final rank for each buffer was determined. Buffer denoted as 1M resulted in no significant difference for cell attachment, confluency, and viability as compared to non-nucleofected controls. Nucleofection in 1M buffer, in the absence of DNA vectors, resulted in increased col2, ki67, ccnd1 mRNA levels, and decreased col1 mRNA levels at 4 days of culture. Flow cytometry revealed that the transfection efficiency of 1M buffer was comparable to that obtained using the Amaxa commercial kit. siRNA designed against lamin A/C resulted in an average reduction of lamin A and C proteins to 19% and 8% of control levels, respectively. This study identifies a cost-effective, efficient method of nonviral nucleofection of bovine-passaged chondrocytes using known buffer formulations. Human-passaged chondrocytes could also be successfully nucleofected in 1M buffer. Thus this method should facilitate cost-efficient gene targeting of cells used for articular cartilage repair in a research setting.Entities:
Keywords: cartilage; chondrocytes; gene therapy; nucleofection; transfection
Year: 2016 PMID: 26958320 PMCID: PMC4749754 DOI: 10.1177/1947603515609399
Source DB: PubMed Journal: Cartilage ISSN: 1947-6035 Impact factor: 4.634
Composition of In-Laboratory-Generated Nucleofection Buffers Used in Study.
| Buffer | Composition |
|---|---|
| PBS | 2.7 mM KCl; 137 mM NaCl; 10 mM Na2HPO4; 1.8 mM KH2PO4 |
| PBSM | 2.7 mM KCl; 137 mM NaCl; 10 mM Na2HPO4; 1.8 mM KH2PO4; 50 mM mannitol |
| 1M | 5 mM KCl; 15 mM MgCl2; 120 mM Na2HPO4/NaH2PO4; 50 mM mannitol |
| 2M | 5 mM KCl; 15 mM MgCl2; 15 mM HEPES; 150 mM Na2HPO4/NaH2PO4; 50 mM mannitol |
| 3P | 5 mM KCl; 15 mM MgCl2; 90 mM NaCl; 10 mM glucose; 0.4 mM Ca(NO3)2; 40 mM Na2HPO4/NaH2PO4 |
| 3H | 5 mM KCl; 15 mM MgCl2; 90 mM NaCl; 10 mM glucose; 0.4 mM Ca(NO3)2; 20 mM HEPES; 75 mM Tris/HCl |
Ranking of In-Laboratory-Generated Nucleofection Buffers Based on Sum of Scores for Cell Attachment, Confluency, Viability, and Transfection Efficiency.
| Buffer | Attachment | Confluency | Live Cells | Efficiency | Sum of Scores | Final Rank | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| % of Control | Score | % of control | Score | % Cells Live | Score | % GFP +ve | Score | |||
| PBS | 21 ± 5 | 6 | 24 ± 4 | 6 | 88 ± 2 | 6 | 51 | 1 | 19 | 5 |
| PBS-M | 25 ± 4 | 5 | 26 ± 4 | 5 | 90 ± 1 | 5 | 34 | 6 | 21 | 6 |
| 1M | 70 ± 10 | 1 | 77 ± 20 | 1 | 97 ± 1 | 1 | 45 | 2 | 5 | 1 |
| 2M | 60 ± 12 | 2 | 71 ± 11 | 3 | 96 ± 1 | 2 | 37 | 5 | 12 | 2-3 |
| 3P | 49 ± 12 | 3 | 73 ± 12 | 2 | 94 ± 3 | 3 | 41 | 4 | 12 | 2-3 |
| 3H | 41 ± 6 | 4 | 40 ± 6 | 4 | 92 ± 4 | 4 | 42 | 3 | 15 | 4 |
Figure 1.Successful nucleofection of passaged chondrocytes using Amaxa buffers. (A) Phase contrast and fluorescent images of bovine-passaged cells transfected with pmaxGFP. Scale bars = 100 µm (B) Flow cytometry of chondrocytes transfected with no vector (bovine), pmaxGFP (human or bovine), and Cignal GFP (bovine) measured by green fluorescent protein (GFP) fluorescence and no siRNA (bovine) or siGLO transfection indicator (bovine) measured by red fluorescent protein (RFP) fluorescence.
Figure 2.Nucleofection of bovine-passaged chondrocytes using specific formulated buffers. (A) Florescent microscopic images of calcein-AM stained chondrocytes 1day following nucleofection. Scale bars = 100 µM. (B) Attachment of cells as a percentage of non-nucleofected control cells as determined by DNA assay. (C) Confluency of cells as a percentage of non-nucleofected control cells calculated through image j analysis. (D) Proportion of live cells as determined by live/dead assay counts. (E) Efficiency of nucleofection for buffers as determined through flow cytometry. *P < 0.05; ^P < 0.01; #P < 0.001, versus control.
Figure 3.Nucleofection of bovine-passaged chondrocytes with pmaxGFP using buffer 1M is similar to transfection with Amaxa buffers as demonstrated through (A) phase contrast and fluorescent microscopy images of passaged chondrocytes (scale bars = 100 µm) and (B) flow cytometry. Passaged bovine chondrocytes nucleofected with no template siRNA (NT) or siRNA designed against lamin A/C. Levels of lamin A and C are evaluated by Western blot analysis (C) and densitometry (D). #P < 0.001, versus NT siRNA.
Figure 4.Effect of nucleofection on bovine-passaged chondrocyte gene expression at (A) 2 and (B) 4 days following nucleofection as compared to non-nucleofected control. Gross appearance of tissue that formed 21 days after nucleofection (C). Histological examination by light microscopy showed a continuous layer of cartilage that is rich in proteoglycan (D). (E) No differences were detected in glycosaminoglycan (GAG) and collagen accumulation by passaged chondrocytes that were nucleofected (Nuc) as compared to non-nucleofected (NN) cells. (C, hematoxylin and eosin; D, toluidine blue; scale bars = 0.5 mm). *P < 0.05; ^P < 0.01; #P < 0.001, versus control.